XFOR
X4 Pharmaceuticals Inc
NASDAQ: XFOR · HEALTHCARE · BIOTECHNOLOGY
$4.07
-0.73% today
Updated 2026-04-30
Market cap
$374.59M
P/E ratio
—
P/S ratio
10.67x
EPS (TTM)
$-1.87
Dividend yield
—
52W range
$1 – $5
Volume
0.5M
X4 Pharmaceuticals Inc (XFOR) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-10.82M | $-21.64M | $-27.87M | $-25.42M | $-48.05M | $-58.82M | $-70.91M | $-77.10M | $-96.51M | $-130.90M | $-85.62M |
| Capital expenditures | $170000.00 | $73000.00 | $42000.00 | $34000.00 | $174000.00 | $1.36M | $615000.00 | $103000.00 | $60000.00 | $7.33M | $3.00M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $126000.00 | $644000.00 | $906000.00 | $5.62M | $2.05M | $5.43M | $6.18M | $5.20M | $8.69M | $8.20M | $4.30M |
| Free cash flow | $-10.99M | $-21.71M | $-27.91M | $-25.45M | $-48.23M | $-60.18M | $-71.52M | $-77.20M | $-96.57M | $-138.23M | $-88.62M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $45.68M | — | $19.95M | $12.39M | $13.94M | $12.00 | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $-47.79M | — | $40.02M | — | — | — |